Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
Keystone, Edward C, Cohen, Stanley B, Emery, Paul, Kremer, Joel M, Dougados, Maxime, Loveless, James E, Chung, Carol, Wong, Pamela, Lehane, Patricia B, Tyrrell, Helen
Published in Journal of rheumatology (01.12.2012)
Published in Journal of rheumatology (01.12.2012)
Get more information
Journal Article
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Cohen, Stanley B., Emery, Paul, Greenwald, Maria W., Dougados, Maxime, Furie, Richard A., Genovese, Mark C., Keystone, Edward C., Loveless, James E., Burmester, Gerd‐Rüdiger, Cravets, Matthew W., Hessey, Eva W., Shaw, Timothy, Totoritis, Mark C.
Published in Arthritis and rheumatism (01.09.2006)
Published in Arthritis and rheumatism (01.09.2006)
Get full text
Journal Article
Dr. Keystone, et al, reply
Published in Journal of rheumatology
(01.05.2013)
Get more information
Journal Article
Programmable lead conditioner
LOVELESS; JAMES E, ANTAO; JOSEPH, GLUCKSMAN; MICHAEL D, WAHAWISAN; WEERAKIAT, ZEMEK; MICHAEL C, HASTEN; PAUL H, BOTKIN; DENNIS M, ROY; RAJIV, MOORE; TROY D
Year of Publication 07.07.1998
Get full text
Year of Publication 07.07.1998
Patent
Lead conditioner for Quad semiconductor packages
LOVELESS; JAMES E, GLUCKSMAN; MICHAEL D, ANTAO; JOSEPH S, BOTKIN; DENNIS M, MOORE; TROY D, DIFLORIA; THOMAS J
Year of Publication 15.06.1993
Get full text
Year of Publication 15.06.1993
Patent
Programmable lead conditioner
HASTEN, PAUL H, MOORE, TROY D, JAMES E. LOVELESS, JOSEPH (NMI) ANTAO, BOTKIN, DENNIS M, GLUCKSMAN, MICHAEL D, WAHAWISAN, WEERAKIAT
Year of Publication 11.04.1999
Get full text
Year of Publication 11.04.1999
Patent